<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Life</journal-id><journal-id journal-id-type="iso-abbrev">J Med Life</journal-id><journal-id journal-id-type="publisher-id">JMedLife</journal-id><journal-title-group><journal-title>Journal of Medicine and Life</journal-title></journal-title-group><issn pub-type="ppub">1844-122X</issn><issn pub-type="epub">1844-3117</issn><publisher><publisher-name>Carol Davila University Press</publisher-name><publisher-loc>Romania</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25408735</article-id><article-id pub-id-type="pmc">4197489</article-id><article-id pub-id-type="publisher-id">JMedLife-07-254</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Presentation</subject></subj-group></article-categories><title-group><article-title>Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of helicobacter pylori: A randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khoshnood</surname><given-names>A</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Hakimi</surname><given-names>P</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Salman-Roghani</surname><given-names>H</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Reza Mirjalili</surname><given-names>M</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1"><label/>Department of Internal Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</aff><author-notes><corresp><bold>Correspondence to:</bold>Asghar Khoshnood, MD,
Department of Internal Medicine, Faculty of Medicine, Shahid Sadoughi Hospital,
Ibn Sina BLVD, Ghandi BLVD, Safayieh, Yazd, Iran
Phone: +98-8224100; +98-, Email: askhoshnood@yahoo.com
</corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>6</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>25</day><month>6</month><year>2014</year></pub-date><volume>7</volume><issue>2</issue><fpage>254</fpage><lpage>259</lpage><history><date date-type="received"><day>19</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>28</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9;Carol Davila University Press
</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is
an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work
is properly cited.</license-p></license></permissions><abstract><p>Abstract</p><p>Background: Eradication of helicobacter pylori is important for treatment of GU but an ideal regimen is not available. HP is resistant to metronidazole and clarithromycin. Clarithromycin is expensive and is not available in under developing countries. This study aimed to compare two regimens containing clarithromycin or azithromycin. </p><p> Methods: Totally, seventy-eight patients with GU (confirmed with endoscopy) and infection of HP (Confirmed by Rapid Urease Test (RUT)) were allocated to one of the groups of study (35 participants in each group). Two weeks regimen of Clarithromycin (2&#x000d7;500 mg) + Amoxicillin (2&#x000d7;1 gr) + omeprazole (2&#x000d7;20 mg) was administered for group A of patients while group B got a 10 days regimen of Azithromycin (1&#x000d7;250 mg) + 14 days Amoxicillin (2&#x000d7;1 gr) + omeprazole (2&#x000d7;20 mg). At the end of the treatment course, the patients were evaluated according to the side effects of the drugs. In addition, two months after the end of therapy, patients underwent endoscopy and biopsy to evaluate HP eradication. </p><p> Results: After two weeks, the side effects of the drug were: Nausea 8 patients in group A and 7 patients in group B, Diarrhea 2 patients in group A, 3 patients in group B and vomiting 2 patients in group A, 3 patients in group B. There were no serious side effects in any group. Eradication rate in group A was 82.9% (based on per protocol analysis (PPA)) and 84.6 % (intention to treat (ITT)). In group B, eradication rate was 77.1 % (PPA) and 79.5 % (ITT) (P=0.55). </p><p> Conclusion: Based on our study results, azithromycin can be used in HP eradication regimen because of its similar efficacy to clarithromycin but also have lower cost, side effects and resistance.
</p></abstract><kwd-group><kwd>Helicobacter Pylori</kwd><kwd>Eradication</kwd><kwd>Azithromycin</kwd><kwd>Clarithromycin</kwd></kwd-group></article-meta></front><body><sec sec-type="Introduction" id="sec1-1"><title>Introduction</title><p>Helicobacter pylori infection is one of the most prevalent gastro intestinal infections worldwide but its prevalence in different countries and population is different, it also has a direct relationship with low socioeconomic situation [<bold><xref rid="R1" ref-type="bibr">1</xref>-<xref rid="R4" ref-type="bibr">4</xref></bold>]. In developed societies, the prevalence is about 20%-50% while in developing countries about 80% of adults are infected [<bold><xref rid="R5" ref-type="bibr">5</xref></bold>]. In Iran reports show that 70.1% of people with gastritis, 86.2% of duodenal ulcer patients and 70% of gastric ulcer patients are infected with helicobacter pylori that will increase by age [<bold><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></bold>]. Although helicobacter pylori infection is asymptomatic in about 90% of the patients but symptomatic ones are related to diseases like gastritis, peptic ulcer (duodenal or gastric), gastric carcinoma and gastric lymphoma [<bold><xref rid="R8" ref-type="bibr">8</xref></bold>]. Infection for more than ten years increases the risk of extra cardia gastric carcinomas three times more. Then its eradication is important for lowering related morbidity [<bold><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></bold>]. </p><p> From the suggestion of helicobacter pylori (HP) as a GI infection about 20 years ago, diagnosis and treatment of peptic ulcer has been changing fundamentally and has become an infectious disease whose eradication with antibiotics can cause remission of the lesions [<bold><xref rid="R11" ref-type="bibr">11</xref>-<xref rid="R13" ref-type="bibr">13</xref></bold>]. </p><p> The current treatments of peptic ulcer have two main effects, the eradication of infection and the decrease of acid production [<bold><xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref></bold>]. This causes a decrease in peptic ulcer recurrence and then a decrease in complications like bleeding, perforation and malignancy development [<bold><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></bold>]. For the eradication of helicobacter pylori, there are different regimens with different drugs and duration of treatments [<bold><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></bold>]. </p><p> The ideal regimen should be cost effective, clinically effective, tolerable and have a short duration [<bold><xref rid="R20" ref-type="bibr">20</xref></bold>]. </p><p> Considering the increasing rate of tolerance to clarithromycin and metronidazole and low resistance to azithromycin, we designed this study to compare two different regimens of helicobacter pylori eradication with clarithromycin or azithromycin. </p><p> Peptic ulcer disease includes gastric and duodenal ulcers. DU and GU have several similarities in signs, symptoms and diagnosis [<bold><xref rid="R21" ref-type="bibr">21</xref></bold>] but also have some discrimination factors. Duodenal ulcers are commonly at the first three centimeters of pylorus and are mostly benign, while gastric ulcers can indicate the cancer formation [<bold><xref rid="R22" ref-type="bibr">22</xref></bold>]. </p><p> Acute helicobacter infection can cause temporary hypochlorydia, but chronic infection can stimulate gastrin and inhibition of somatostatine and then stimulation of acid secretion and increase in basal acid output (BAO) [23,24]. The bacteria would not invade the mucosa but adhere to epithelial cells and cause mentioned inflammatory response [<bold><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R21" ref-type="bibr">21</xref></bold>]. </p><p> Epidermal Growth Factor (EGF) and Transforming Growth Factor Bata (TGF&#x003b2;) are potent inhibitors of acid secretion and protectors of mucosa growth, HP eradication can cause EGF secretion and ulcer recovery [<bold><xref rid="R21" ref-type="bibr">21</xref></bold>]. Evidence shows that only species of HP that produce cytotoxins related to Cag A gene can be pathogen. About 85%-100% of the patients with Duodenal Ulcer (DU) have this type of HP infection [<bold><xref rid="R25" ref-type="bibr">25</xref></bold>]. </p><p> Helicobacter Pylori is a gram-negative bacillus that lives in the gastric mucosa, spiral shape and also flagellums of this bacterium causing motility in the gastric mucosa. Production of urease causes its resistance to acids. Human is the only reservoir of this bacterium [<bold><xref rid="R26" ref-type="bibr">26</xref></bold>]. </p><p> Azithromycin is an antibiotic from the new macrolides class that inhibits protein synthesis in bacterium and is based on drug concentration; it can be bacteriostatic or bactericide. This drug has favorable gastrointestinal absorption as it works against both gram negative and positive bacteria with good distribution in all body organs except for CNS, will not be metabolized and its clearance is mainly done by the bile [<bold><xref rid="R27" ref-type="bibr">27</xref></bold>]. </p><p> Diagnosis of HP is by non-invasive or invasive (endoscopy and biopsy) ways. Non-invasive tests include UBT (Urease Breath Test), serologic tests and stool antigen detection test. Invasive tests are Rapid Urease Test (RUT), biopsy and culture that specimen will get by endoscopy and biopsy from antrum. The best test is RUT with 80%-95% sensitivity and 95%-100% specificity [<bold><xref rid="R28" ref-type="bibr">28</xref></bold>]. </p><p> Histological study of specimen obtained by biopsy of antrum is the gold standard of diagnosis with sensitivity and specificity of more than 95% and 98% respectively that can show inflammation, metaplasia, dysplasia or even neoplasia [<bold><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></bold>]]. </p><p> The treatment of peptic ulcer starts with HP eradication that must be accompanied by PPI (Proton Pump Inhibitors) like Omeprazole. In addition, the patient must avoid smoking and alcohol use. Eradication of HP is difficult and multiple antibiotics must be used for weeks [<bold><xref rid="R30" ref-type="bibr">30</xref></bold>]. </p><p> At present, there are several treatment protocols for treatment. Standard protocols are Omeprazole+metronodazole+amoxycilin+tetracycline and clarithromycin+amoxycilin+omeprazole. Latest guidelines in US and Europe suggest two weeks of antibiotic treatment [<bold><xref rid="R31" ref-type="bibr">31</xref>-<xref rid="R33" ref-type="bibr">33</xref></bold>]. </p><p> Confirmation of the eradication is done by non-invasive tests with high sensitivity and specificity. Urea Breath Test (UBT) is the choice. Stool antigen test is another alternative test; eradication must be confirmed at least six weeks after the end of treatment. </p><p> Resistance of HP to clarithromycin has been increased to 15%-20% based on some recent studies and some studies recommended that in regions whose resistance to clarithromycin is higher than 20% or the patient got a macrolide previously, triple therapy with clarithromycin must not be used. </p><p> Considering the lack of evidence on the rate of resistance to clarithromycin in our community and also the lack of evidence which compares the effectiveness of azithromycin with clarithromycin we designed this study to compare the effectiveness of regimens with clarithromycin or azithromycin on helicobacter pylori eradication.
</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><p>This randomized clinical trial was carried out from October 2010 to September 2011 in Shahid Sadoughi Hospital and Khatam-al-Anbia Clinic, Yazd, Iran. After the confirmation of the university&#x02019;s institutional ethics committee, the study was registered in clinical trials.gov as NCT01667692. Thirty-five patients were needed for each group (with consideration of the following parameters: p&#x0003c;0.05 as significance, test power of 80%, d=1.5 and based on previous studies S=2). Patients were selected from people who presented in the Gastroenterology Clinic of Shahid Sadoughi Hospital and Khatam-al-Anbia Paraclinic of Shahid Sadoughi University of Medical Science, have proved duodenal or gastric ulcer by endoscopy and biopsy and had infection of HP by RUT. A written consent was taken from all the patients before starting the study. The indication of treatment was based on the Health Institute of Europe guideline including peptic ulcer, chronic gastritis, maltoma and intestinal metaplasia. Before the study, block randomization was performed according to age and sex of the patients on 78 who did not have study exclusion criteria and did not prove any HP infection. </p><p> Exclusion criteria of study were age below 18 and more than 80, history of renal and liver diseases, sensitivity to study drugs, history of GI bleeding, history of constant NSAID using, pregnancy, use of antibiotics or bismuth for four weeks before the study. </p><p> Group A got a two weeks regimen of clarithromycin 500 mg at every 12 hours (Bd), Amoxicillin 1 geram at every 12 hours and omeprazole 20 mg at every 12 hours. Group B got a 10 days regimen of Azithromycin 250 mg daily, two weeks of amoxicillin 1 geram at every 12 hours and omeprazole 20 mg at every 12 hours. Drugs were obtained from the same brand. </p><p> During the study, patients were followed by phone calls so as not to forget to take their drugs. After finishing the treatment period, the patients were invited to the clinic for checking drugs&#x02019; side effects. Patients were requested to retain their drugs sachets and bring them to the clinic. While counting remnant drug, the patients` compliance was estimated. Patients who have used more than 80% of their administered drugs were taken as good compliance. Side effects like headache, nausea, vomiting, abdominal pain and dizziness was detected by self-report of patients. In addition, the clinical examination according to rash and epigastric pain was done. Two months after the treatment completion, all endoscopy and biopsy was done for all the patients. One sample from antrum and another from body of stomach were obtained. All specimen stained by modified Gimsa staining and studied by a pathologist was blinded to the patients&#x02019; group.</p><p>The patients&#x02019; demographic information, smoking, drug history and finding of clinical examinations, endoscopy, RUT and results of biopsy two months after the treatment completion were registered in a questionnaire. </p><p> All the registered data were transformed into SPSS 15 software and analyzed by Chi-square, Fisser exact test and T-test. Significant level was taken as P&#x0003c;0.05.
</p></sec><sec sec-type="Results" id="sec1-3"><title>Results</title><p>Totally, 78 patients were included in the study (39 patients from each group). Two patients in group A and one patient in group B discontinued treatment because of drugs side effects. Moreover, two patients from group A and three patients from group B did not attend the follow up session (lost to follow up). Finally, 70 patients (35 from each group) were included in the analysis. The flow of the study is indicated in the Fig 1.</p><fig id="F1" position="float"><label>Fig. 1</label><caption><p>Flow of the study</p></caption><graphic xlink:href="JMedLife-07-254-g001"/></fig><p> The mean age of group A was 41.8&#x000b1;14 and in group B was 41.26&#x000b1;14.39 (P=0.87; T-test). Moreover, the difference between the groups according to sex was not significant (0.329). In addition, groups according to smoking was not significant (P=1.00). </p><p> The prevalence of drug side effects was assessed by two statistical methods of PPA (Per Protocol Analysis) and ITT (Intention To Treat). In the PPA method, 25.7% of group A patients and 31.4% of patients in group B had Side effects (P=0.59). In ITT method, these values were 23% and 28.2% in groups A and B respectively (P=0.61). </p><p> The rate of HP eradication also was assessed by ITT and PPA analysis methods that were not significantly different between groups (P=0.55 and P= 0.55 respectively) (<bold><xref ref-type="table" rid="T1">Table 1</xref></bold>). </p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Drugs side effects in groups of study based on Pre Protocol Analysis (PPA) and intention to treat (ITT) and related P-Values</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Groups/Side Effect</th><th align="center" rowspan="1" colspan="1">A
35
</th><th align="center" rowspan="1" colspan="1">B
35
</th><th align="center" rowspan="1" colspan="1">P-Value
(Chi-Square)
</th></tr></thead><tbody><tr><th align="left" rowspan="1" colspan="1">Per Protocol </th><th align="left" rowspan="1" colspan="1">9</th><th align="left" rowspan="1" colspan="1">11</th><th align="left" rowspan="1" colspan="1">0.59</th></tr><tr><th align="left" rowspan="1" colspan="1">Analysis (PPA)</th><th align="left" rowspan="1" colspan="1">25.5%</th><th align="left" rowspan="1" colspan="1">31.4%</th><th align="left" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Intention To Treat</th><th align="left" rowspan="1" colspan="1">23%</th><th align="left" rowspan="1" colspan="1">28.2%</th><th align="left" rowspan="1" colspan="1">0.61</th></tr></tbody></table></table-wrap></sec><sec sec-type="Discussion" id="sec1-4"><title>Discussion</title><p>Helicobacter pylori infection is an important risk factor of peptic ulcer, chronic gastritis, maltoma and gastric adenocarcinoma and its eradication can be effective in the treatment and prevention of these diseases [34,35]. Several treatment regimens were suggested but none of them was ideal. Also, several studies were done on the type of drugs, dosage and duration of treatment that had contradictory results [<bold><xref rid="R36" ref-type="bibr">36</xref></bold>]. </p><p> Several factors were considered in the treatment regimens; cost of drugs, effectiveness, side effects and duration of drug use is needed [<bold><xref rid="R36" ref-type="bibr">36</xref></bold>]. Rate pf HP eradication has been estimated to more than 95% until 1995 [<bold><xref rid="R37" ref-type="bibr">37</xref></bold>] by using the triple regimen of PPI, amoxicillin and clarithromycin, but this regimen now has a success rate lower than 80%, that the most common cause of failure is drug resistance [<bold><xref rid="R38" ref-type="bibr">38</xref></bold>]. Because of this fact, searching for a newer generation of drugs, especially a new generation of macrolides like azithromycin, has been considered by researchers [<bold><xref rid="R39" ref-type="bibr">39</xref></bold>]. Azithromycin is resistant in acidotic environment of stoma, has a longer half life and a higher concentration in stomach tissues after oral administration of 500 mg. Its concentration will be stable on 90 mg in stomach tissue that is higher than its concentration in the plasma [<bold><xref rid="R40" ref-type="bibr">40</xref>,<xref rid="R7" ref-type="bibr">7</xref></bold>]. </p><p> In our study based on PPA analysis HP eradication regimen with azithromycin and clarithromycin had 79.5% and 83.9% success rates, respectively (P=0.55) and in ITT analysis had 79.5% and 84.6% success rates respectively (P=0.555). Also, there was no significant difference between two groups according to drugs side effects. </p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>HP eradication Success rate in groups of study based on Pre Protocol Analysis (PPA) and Intention To Treat (ITT) and related P-Values</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Groups/Eradication Success</th><th align="center" rowspan="1" colspan="1">A
39
</th><th align="center" rowspan="1" colspan="1">B
39
</th><th align="center" rowspan="1" colspan="1">P-Value
(Chi-Square)
</th></tr></thead><tbody><tr><th align="left" rowspan="1" colspan="1">Per Protocol </th><th align="left" rowspan="1" colspan="1">29</th><th align="left" rowspan="1" colspan="1">27</th><th align="left" rowspan="1" colspan="1">0.55</th></tr><tr><th align="left" rowspan="1" colspan="1">Analysis (PPA)</th><th align="left" rowspan="1" colspan="1">82.9%</th><th align="left" rowspan="1" colspan="1">77.1%</th><th align="left" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Intention To Treat</th><th align="left" rowspan="1" colspan="1">84.6%</th><th align="left" rowspan="1" colspan="1">79.5%</th><th align="left" rowspan="1" colspan="1">0.55</th></tr></tbody></table></table-wrap><p> In 2002, Solivan et al results showed the results in their study based on the fact that clarithromycin had better responses contrasting with azithromycin and then azithromycin was not suggested in that study [<bold><xref rid="R42" ref-type="bibr">42</xref></bold>]. </p><p> In 2003, Laurent et al mentioned that the success rate of clarithromycin was calculated to 72% while azithromycin only had 38% success rate [<bold><xref rid="R34" ref-type="bibr">34</xref></bold>]. In 2008, Fernando et al reached similar results, while HP eradication rate of azithromycin was 38% and, based on this study results, azithromycin was not suggested except for its low cost and good compliance [<bold><xref rid="R43" ref-type="bibr">43</xref></bold>]. The results of these studies are not concomitant with our study. </p><p> In their study, Avec et al calculated the eradication success rate of regimen with azithromycin at about 78% and clarithromycin at 81%, which were similar to our study results [<bold><xref rid="R44" ref-type="bibr">44</xref></bold>]. In Russia, after the comparison of eradication regimens containing azithromycin with regimen that included metronidazole, Ivashkin et al concluded that azithromycin could be an effective drug in HP eradication treatment regimens [<bold><xref rid="R39" ref-type="bibr">39</xref></bold>]. In a Meta analysis done by Dong et al in China, in 2009, after the inclusion of fourteen studies in the Meta analysis, it was concluded that azithromycin is an effective drug in HP eradication with low side effects [<bold><xref rid="R45" ref-type="bibr">45</xref></bold>]. Results of these studies are concomitant with our study. </p><p> Regarding cost effectiveness, in Iran, the cost of drugs that was used in our group A (regimen with azithromycin) will be of about $ 1.5 while this cost for drug regimen of group B is of about $ 4.5. </p></sec><sec sec-type="Conclusion" id="sec1-5"><title>Conclusion</title><p>It seems that azithromycin can be used in HP eradication regimen that has similar efficacy to clarithromycin but also has lower cost and side effects. Using this drug will not increase the success rate of HP eradication but also its lower side effects and the cost effectiveness will not justify its using. Then, based on our study, the suggestion will be made to include this drug in the treatment drug regimens of helicobacter pylori. Also, we suggested the combination of other drugs like metronidazole with azithromycin to evaluate the success rate of eradication. </p></sec></body><back><fn-group><fn id="FN1" fn-type="financial-disclosure"><p>This study was under financial support of Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran as part of Dr. Parisa Hakimi dissertation to be graduated as internist. Other authors declare no conflict of interest.</p></fn><fn id="FN2" fn-type="conflict"><p>Disclosures and Conflicts of Interest: None specified</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner </surname><given-names>P</given-names></name><name><surname>Megraud </surname><given-names>F</given-names></name></person-group><article-title>European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report</article-title><source>Aliment Pharmacol Ther</source><year>2002</year><volume>16</volume><fpage>167</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">11860399</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>2. NIH consensus Statement</surname></name></person-group><article-title>Helicobacter pylori in peptic ulcer disease</article-title><source>JAMA</source><year>1994</year><volume>12</volume><fpage>1</fpage><lpage>23</lpage></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>3. American Digestive Health Foundation</surname></name></person-group><article-title>International update conference on Helicobacter pylori</article-title><source>Gastroenterology</source><year>1997</year><volume>113</volume><fpage>54</fpage><lpage>58</lpage></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howden </surname><given-names>C</given-names></name><name><surname>Hunt </surname><given-names>R</given-names></name></person-group><article-title>Guidelines for the management of Helicobacter pylori infection</article-title><source>Am J Gastroentrol</source><year>1998</year><volume>93</volume><fpage>2330</fpage><lpage>2338</lpage></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everhart </surname><given-names>JE</given-names></name><name><surname>Kruszon-Moran </surname><given-names>D</given-names></name></person-group><article-title>Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States</article-title><source>J Infect Dis</source><year>2000</year><volume>181</volume><fpage>1359</fpage><lpage>1363</lpage><pub-id pub-id-type="pmid">10762567</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suerbaum </surname><given-names>S</given-names></name><name><surname>Michetti </surname><given-names>P</given-names></name></person-group><article-title>Helicobacter pylori infection</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>1175</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">12374879</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talley </surname><given-names>NJ</given-names></name><name><surname>Vakil </surname><given-names>N</given-names></name></person-group><article-title>Guidelines for the management of dyspepsia</article-title><source>Am J Gastroenterol</source><year>2005</year><volume>100</volume><fpage>2324</fpage><lpage>2327</lpage><pub-id pub-id-type="pmid">16181387</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst </surname><given-names>PB</given-names></name><name><surname>Peura </surname><given-names>DA</given-names></name></person-group><article-title>The translation of Helicobacter pylori basic research to patient care</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>188</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">16401482</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa </surname><given-names>P</given-names></name><name><surname>Houghton </surname><given-names>J</given-names></name></person-group><article-title>Carcinogen of Helicobacter pylori.</article-title><source>Gastroenterology </source><year>2007</year><volume>133</volume><fpage>659</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">17681184</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amieva </surname><given-names>MR</given-names></name><name><surname>El-Omar </surname><given-names>EM</given-names></name></person-group><article-title>Host-bacterial interactions in Helicobacter pylori infection</article-title><source>Gastroenterology</source><year>2008</year><volume>134</volume><fpage>6</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">18166339</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chey </surname><given-names>WD</given-names></name><name><surname>Wong </surname><given-names>BC</given-names></name></person-group><article-title>American College of Gastroenterology guideline on the management of Helicobacter pylori infection</article-title><source>Am J Gastroenterol</source><year>2007</year><volume>102</volume><fpage>1808</fpage><lpage>1825</lpage><pub-id pub-id-type="pmid">17608775</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner </surname><given-names>P</given-names></name><name><surname>Kirchner </surname><given-names>T</given-names></name></person-group><article-title>Helicobacter pylori eradication and gastric ulcer healing&#x02014;Comparison of three pantoprazole-based triple therapies. BYK Advanced Gastric Ulcer Study Group</article-title><source>Aliment Pharmacol Ther</source><year>2003</year><volume>17</volume><fpage>1125</fpage><lpage>1135</lpage><pub-id pub-id-type="pmid">12752349</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higuchi </surname><given-names>K</given-names></name><name><surname>Fujiwara </surname><given-names>Y</given-names></name></person-group><article-title>Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori?. A randomized, controlled, prospective study</article-title><source>Aliment Pharmacol Ther</source><year>2003</year><volume>17</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">12492739</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peitz </surname><given-names>U</given-names></name><name><surname>Menegatti </surname><given-names>M</given-names></name></person-group><article-title>The European meeting on Helicobacter pylori: Therapeutic news from Lisbon</article-title><source>Gut</source><year>1998</year><volume>43</volume><fpage>S66</fpage><lpage>S69</lpage><pub-id pub-id-type="pmid">9764044</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford </surname><given-names>AC</given-names></name><name><surname>Delaney </surname><given-names>BC</given-names></name></person-group><article-title>Eradication therapy in Helicobacter pylori positive peptic ulcer disease: Systematic review and economic analysis</article-title><source>Am J Gastroenterol</source><year>2004</year><volume>99</volume><fpage>1833</fpage><lpage>1855</lpage><pub-id pub-id-type="pmid">15330927</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaspersen </surname><given-names>D</given-names></name><name><surname>Koerner </surname><given-names>T</given-names></name></person-group><article-title>Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage</article-title><source>Gastrointest Endosc</source><year>1995</year><volume>41</volume><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7698624</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laine </surname><given-names>L</given-names></name><name><surname>Hopkins </surname><given-names>RJ</given-names></name></person-group><article-title>Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated?. A meta-analysis of rigorously designed trials</article-title><source>Am J Gastroenterol</source><year>1998</year><volume>93</volume><fpage>1409</fpage><lpage>1415</lpage><pub-id pub-id-type="pmid">9732917</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jodlowski </surname><given-names>TZ</given-names></name><name><surname>Lam </surname><given-names>S</given-names></name></person-group><article-title>Emerging therapies for the treatment of Helicobacter pylori infections</article-title><source>Ann Pharmacother</source><year>2008</year><volume>42</volume><fpage>1621</fpage><lpage>1639</lpage><pub-id pub-id-type="pmid">18845620</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung </surname><given-names>JJ</given-names></name><name><surname>Chung </surname><given-names>SC</given-names></name></person-group><article-title>Antibacterial treatment of gastric ulcers associated with Helicobacter pylori</article-title><source>N Engl J Med</source><year>1995</year><volume>332</volume><fpage>139</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">7800005</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alarcyon </surname><given-names>T</given-names></name><name><surname>Domingo </surname><given-names>D</given-names></name></person-group><article-title>Antibiotic resistance problems with Helicobacter pylori</article-title><source>Int J Antimicrob Agents</source><year>1999</year><volume>12</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">10389643</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min </surname><given-names>K</given-names></name><name><surname>Hong </surname><given-names>SM</given-names></name></person-group><article-title>Intramucosal helicobacter pylori in the human and murine stomach: Its relationship to the inflammatory reaction inhuman Helicobacter pylori gastritis</article-title><source>Pathol Res Pract</source><year>2003</year><volume>199</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12650511</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Versalovic </surname><given-names>J</given-names></name></person-group><article-title>Helicobacter pylori. Pathology and diagnostic strategies</article-title><source>Am J Clin Pathol</source><year>2003</year><volume>119</volume><fpage>403</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">12645343</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee </surname><given-names>A</given-names></name></person-group><article-title>The Helicobacter pylori genome&#x02014;New insights into pathogenesis and therapeutics</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>832</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">9504947</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amieva </surname><given-names>MR</given-names></name><name><surname>El-Omar </surname><given-names>EM</given-names></name></person-group><article-title>Host-bacterial interactions in Helicobacter pylori infection</article-title><source>Gastroenterology</source><year>2008</year><volume>134</volume><fpage>6</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">18166339</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillen </surname><given-names>D</given-names></name><name><surname>McColl </surname><given-names>KE</given-names></name></person-group><article-title>Gastroduodenal disease, Helicobacter pylori, and genetic polymorphisms</article-title><source>Clin Gastroenterol Hepatol</source><year>2005</year><volume>3</volume><fpage>1180</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">16361041</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown </surname><given-names>LM</given-names></name></person-group><article-title>Helicobacter pylori: Epidemiology and routes of transmission</article-title><source>Epidemiol Rev</source><year>2000</year><volume>22</volume><fpage>283</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">11218379</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blandizzi </surname><given-names>C</given-names></name><name><surname>Malizia </surname><given-names>T</given-names></name></person-group><article-title>Gastric mucosal distribution andclinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis</article-title><source>J Antimicrob Chemother</source><year>1998</year><volume>42</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">9700531</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishikawa </surname><given-names>K</given-names></name><name><surname>Sugiyama </surname><given-names>T</given-names></name></person-group><article-title>A prospective evaluation of new rapid urease test before and after eradication Treatment of Helicobacter Pylori in comparison with histology, culture and c-urea breath test</article-title><source>Gastrointest Endosc</source><year>2000</year><volume>51</volume><fpage>164</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">10650258</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahner </surname><given-names>E</given-names></name><name><surname>Vaira </surname><given-names>D</given-names></name></person-group><article-title>Role of noninvasive tests (C-urea breath test and stool antigen test) as additional tools in diagnosis of Helicobacter pylori infection in patients with atrophic body gastritis</article-title><source>Helicobacter</source><year>2004</year><volume>9</volume><fpage>436</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">15361083</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Megraud </surname><given-names>F</given-names></name></person-group><article-title>Resistance of Helicobacter pylori to antibiotics and its impact on treatment options</article-title><source>Drug Resist Update</source><year>2001</year><volume>4</volume><fpage>178</fpage><lpage>186</lpage></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagahara </surname><given-names>A</given-names></name><name><surname>Miwa </surname><given-names>H</given-names></name></person-group><article-title>Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen</article-title><source>J Gastroenterol</source><year>2004</year><volume>39</volume><fpage>1051</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">15580397</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattahi </surname><given-names>E</given-names></name><name><surname>Motamedi </surname><given-names>R</given-names></name></person-group><article-title>Triple therapy using two dosages of metronidazole along with amoxicillin and omeprazole to eradicate Helicobacter pylori infection: A randomized, open study</article-title><source>Indian J Gastroenterol</source><year>2004</year><volume>23</volume><fpage>154</fpage><pub-id pub-id-type="pmid">15333981</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roghani </surname><given-names>HS</given-names></name><name><surname>Massarrat </surname><given-names>S</given-names></name></person-group><article-title>Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains</article-title><source>Eur J Gastroenterol Hepatol</source><year>1999</year><volume>11</volume><fpage>709</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">10445787</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurent </surname><given-names>J</given-names></name><name><surname>Megraud </surname><given-names>F</given-names></name></person-group><article-title>A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.</article-title><source>Aliment Pharmacol Ther</source><year>2001</year><volume>15</volume><fpage>1787</fpage><lpage>1793</lpage><pub-id pub-id-type="pmid">11683693</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebrahimi-Dariani </surname><given-names>N</given-names></name><name><surname>Mirmomen </surname><given-names>S</given-names></name></person-group><article-title>The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients</article-title><source>Med Sci Monit</source><year>2003</year><volume>9</volume><fpage>PI105</fpage><lpage>PI108</lpage><pub-id pub-id-type="pmid">12942042</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gumurdulu </surname><given-names>Y</given-names></name><name><surname>Serin </surname><given-names>E</given-names></name></person-group><article-title>Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey</article-title><source>World J Gastroenterol</source><year>2004</year><volume>10</volume><fpage>668</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">14991935</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciociola </surname><given-names>AA</given-names></name><name><surname>McSorley </surname><given-names>DJ</given-names></name></person-group><article-title>Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated</article-title><source>Am J Gastroenterol</source><year>1999</year><volume>94</volume><fpage>1834</fpage><pub-id pub-id-type="pmid">10406244</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellenrieder </surname><given-names>V</given-names></name><name><surname>Boek </surname><given-names>W</given-names></name></person-group><article-title>Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication</article-title><source>Scand J Gastroentrol</source><year>1999</year><volume>34</volume><fpage>750</fpage><lpage>756</lpage></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivashkin </surname><given-names>VT</given-names></name><name><surname>Lapina </surname><given-names>TL</given-names></name></person-group><article-title>Azithromycin in a triple therapy for H. pylori eradication in active duodenal ulcer</article-title><source>World J Gastroenterol</source><year>2002</year><volume>8</volume><fpage>879</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">12378634</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva </surname><given-names>FM</given-names></name><name><surname>Eisig </surname><given-names>JN</given-names></name></person-group><article-title>Low efficacy of an ultra-short term, once-daily dose triple therapy with omeprazole, azithromycin, and secnidazole for Helicobacter pylori eradication in peptic ulcer</article-title><source>Rev Hosp Clin Fac Med Sao Paulo</source><year>2002</year><volume>57</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">12170343</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krichhoff </surname><given-names>RM</given-names></name><name><surname>Laufen </surname><given-names>H</given-names></name></person-group><article-title>Determination of azithromycin in gastric biopsy samples</article-title><source>Int J Clin Pharmacol Ther</source><year>1999</year><volume>37</volume><fpage>361</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">10442511</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan </surname><given-names>B</given-names></name><name><surname>Coyle </surname><given-names>W</given-names></name></person-group><article-title>Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori</article-title><source>Am J Gastroenterol</source><year>2002</year><volume>97</volume><fpage>2536</fpage><lpage>2539</lpage><pub-id pub-id-type="pmid">12385435</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernando </surname><given-names>M</given-names></name><name><surname>Jaime </surname><given-names>N</given-names></name></person-group><article-title>Short term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance but low efficacy</article-title><source>BMC Gastroenterology</source><year>2008</year><volume>5</volume><fpage>403</fpage><lpage>900</lpage></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vcev </surname><given-names>A</given-names></name><name><surname>Stimac </surname><given-names>D</given-names></name></person-group><article-title>Pantoprazole, amoxicillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients</article-title><source>Aliment Pharmacol Ther</source><year>2000</year><volume>14</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">10632647</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong </surname><given-names>J</given-names></name><name><surname>Yu </surname><given-names>X</given-names></name></person-group><article-title>Azithromycin containing versus standard triple therapy for Helicobacter Pylorii eradication: A meta analysis</article-title><source>World J Gastroenterol</source><year>2009</year><volume>15</volume><fpage>6102</fpage><lpage>6110</lpage><pub-id pub-id-type="pmid">20027685</pub-id></element-citation></ref></ref-list></back></article>